Cortexin vs Davunetide (NAP/AL-108)
Research Verdict
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Quick Answers
Which is better, Cortexin or Davunetide (NAP/AL-108)?
Neither compound has a universal evidence advantage. Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
What is the key difference between Cortexin and Davunetide (NAP/AL-108)?
Davunetide is a defined synthetic peptide (NAP) with known negative Phase 3 results; cortexin is a poorly characterized bovine brain-derived polypeptide mixture - different levels of molecular definition and regulatory transparency.
Evidence Comparison
Davunetide: Phase 2/3 for PSP (Boxer 2014, Lancet Neurol) - failed primary endpoint in a well-designed Western trial. Cortexin: Russian clinical studies claiming neuroprotective effects, but data is not independently validated and comes from bovine brain extract. Neither has positive Western-standard evidence.
Evidence Context Favoring Cortexin
Russian clinical practice contexts where cortexin is approved and accessible.
Evidence Context Favoring Davunetide (NAP/AL-108)
Research requiring a molecularly defined neuroprotective peptide with published Phase 2/3 data, even if the trial was negative.
Side-by-Side Snapshot
| Evidence grade | Cortexin: Level C Davunetide (NAP/AL-108): Level C |
|---|---|
| Research status | Cortexin: Approved Outside US Davunetide (NAP/AL-108): Phase 2 |
| Primary category | Cortexin: Cognitive & Nootropic Davunetide (NAP/AL-108): Cognitive & Nootropic |
| Cited studies | Cortexin: 2 Davunetide (NAP/AL-108): 3 |